Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people ...

You don’t realize that you could be sleeping for eight hours but when you get tested you actually only slept for one or two.” ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on January 13.Stay Ahead of the ...

The company develops minimally invasive solutions for patients with obstructive sleep apnea ... expand Inspire’s total addressable market by causing more people with obesity to seek treatment ...

Obstructive Sleep Apnea affects 1 in 15 Americans, likely more, and treatment has often involved inconvenient treatments like CPAP machines. A new device called Inspire offers new alternatives for ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

There is a need for convenient methods for detecting apnea ... individualized treatment. Lisa Strauss, PhD, is a clinical psychologist in the Boston area. She specializes in sleep disorders.

Inspire is a medical technology ... of its kind that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please ...